Defence ramp in focus: profitability meets expansion capex
JAYKAY trades between two forces — aggressive defence/aerospace investment and near-term margin compression. Q2 will show whether order intake momentum justifies the capex blitz and rights issue.
The setup: transition or pivot?
JAYKAY's story has inverted. For two decades a precision machining and composites house, the company is now—aggressively—a defence/aerospace platform. The Board approved ₹100 crore in loans to JK Defence & Aerospace, plus ₹27 crore in preference share infusions into defence and digital subsidiaries. Allen Reinforced Plastics (a step-down subsidiary) landed a ₹60 crore order from BrahMos Aerospace. The company just snagged AS9100D and ISO 9001:2015 certifications—the defence playbook standard. All of this while running a ₹155 crore rights issue to fund growth. This is not a margin-accretion story. This is capital reallocation. Q2 will show if the order book justifies the burn.
~₹75–85 Cr
Q1 FY27 ran ₹76.8 Cr; Q2 FY26 was ₹68.8 Cr. Trendline says revenue is stabilizing around ₹75–80 Cr per quarter.
~₹5–8 Cr
Q1 plunged 78% YoY to ₹4.5 Cr. Recovery hinges on subsidiary contribution and COGS absorption. Margin expansion not the watch.
~14–16%
Q1 FY27 implied ~16.7% (EBITDA not disclosed in our data). Q2 FY26 was ~16.8%. Watch for compression if defence ramp is pre-revenue.
₹60+ Cr
BrahMos order alone is a year-plus of revenue visibility. Medical device license opens new pipeline.
What a strong print looks like: Q2 revenue tracking ₹80+ Cr quarter-on-quarter growth; order intake/backlog commentary pointing to ₹100+ Cr visibility; subsidiary (especially JK Defence) showing early traction; guidance reaffirmed or raised for FY27. Margins don't need to recover—just stabilize above 14%.
What a weak print looks like: Q2 revenue dipping below ₹75 Cr (demand miss); net profit below ₹3 Cr (capex/absorption burn too steep); no incremental order colour or guidance; subsidiary losses offsetting core profitability; rights issue uptake commentary weak.
Street view: targeted at ₹225, bull ₹275
On track for FY27 guidance?
No explicit full-year FY27 guidance is visible in disclosures. FY26 delivered ₹215.65 Cr net profit (boosted by a large investment gain; operating profit was far lower). Without a formal guide to pin to, the question is whether management colour on defence subsidiary ramp, order book, and margin inflection point shapes Street expectations. Q2 is the first chance to reset that frame.
Since last quarter: capex blitz and strategic repositioning
Oct 22
Medical device manufacturing license (CDSCO Class C) for subsidiary JK Digital
New revenue stream unlocked; regulatory de-risking
Oct 08
₹100 Cr loan facility to JK Defence & Aerospace
Capex signal; debt-funded growth in defence arm
Oct 05
₹25 Cr preference share investment in JK Defence; ₹2 Cr in JK Digital
Equity infusion mirrors loan — serious capex cycle
Sep 29
80th AGM held; FY26 annual report tabled
Governance routine; no activist commentary evident
Sep 25
Trading window closure pre-result announcement
Standard compliance
Sep 23
Rights issue: 2.05 Cr partly paid shares at ₹75; allotment + listing
Capital raise live; promoters did not subscribe above commitment. Small DII/FII take-up signals caution.
Sep 18
AS9100D + ISO 9001:2015 certifications awarded
Defence/aerospace quality gates cleared; positioning for larger contracts
Aug 25
BrahMos Aerospace order: ₹60 Cr to subsidiary Allen Reinforced Plastics
Flagship order; ₹60 Cr visibility over 12–18 months; validates strategy
Headline: The past 10 weeks reveal a company doubling down on defence/aerospace. Three channels: debt, equity, and capex infusions to subsidiaries. The BrahMos order is the proof point—large enough to drive revenue for over a year. But the rights issue's muted uptake and minimal FII/DII interest suggest Street skepticism on timing of profitability inflection. Watch whether management's Q2 commentary de-risks the narrative.
What to watch on result day
1 · Order book & visibility
The BrahMos order is live. Are there others? Board commentary on order pipeline, execution timeline, and visibility beyond Q3 will define sentiment. Any colour on medical device licence takeup or defence wins from newer certifications?
2 · Margin stabilization & subsidiary contribution
Q1 net profit crashed 78% despite revenue growth. Was that one-time absorption, capex ramp, or demand miss? Q2 profit should stabilize north of ₹5 Cr if capex is behind us; below ₹4 Cr is a red flag. Watch for consolidated vs standalone split—are subsidiaries showing early losses or gains?
3 · FY27 guidance & rights issue capital deployment
No prior FY27 guide exists. Will management shape expectations for full-year revenue, profit, and capex peak? Clarity on rights issue capital use (capex complete vs ongoing) and timeline to defence subsidiary breakeven will anchor Street forecasts. Any update on promoter pledging or further equity raises planned?
JAYKAY has entered a multi-year transformation: from a specialty machining and composites supplier to a defence/aerospace platform. Q2 FY27 is the proof-of-concept quarter. Revenue should hold near ₹75–85 Cr, but the Street is watching order intake, subsidiary margin trajectory, and whether capex burn justifies the rights issue capital raise. The stock trades 8% below analyst consensus target (₹225 vs ₹208.6), suggesting the market is pricing in execution risk on the defence pivot. Weak margins this quarter are tolerable only if they buy order backlog; a miss on both fronts re-opens downside to ₹150 (bear case). Certifications landed, flagship order signed. The execution bar for Q2 is clarity on next-phase growth and a credible path to profitability inflection by H2 FY27.
Informational and educational content only. Not investment advice.